Ultra-Mutation in
IDH wild-type
POLE
giant cells
glioblastoma
mismatch repair
tumour mutation load
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Aug 2019
30 Aug 2019
Historique:
received:
08
08
2019
revised:
27
08
2019
accepted:
27
08
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
5
9
2019
Statut:
epublish
Résumé
Glioblastomas (GBMs) are classified into isocitrate dehydrogenase ( Sixteen Eight (50%) We identified a hyper-mutated subgroup among IDH-wt GBMs in adults < 55 years that had improved prognosis. Two cases were ultra-mutated and characterized by the presence of at least 25% giant cells, MMR mutations, and MSI. Since high TML has been associated with response to immune checkpoint inhibition in paediatric gliomas, the identification of a subtype of ultra-mutated IDH-wt GBM may have implications for immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastomas (GBMs) are classified into isocitrate dehydrogenase (
METHODS
METHODS
Sixteen
RESULTS
RESULTS
Eight (50%)
CONCLUSIONS
CONCLUSIONS
We identified a hyper-mutated subgroup among IDH-wt GBMs in adults < 55 years that had improved prognosis. Two cases were ultra-mutated and characterized by the presence of at least 25% giant cells, MMR mutations, and MSI. Since high TML has been associated with response to immune checkpoint inhibition in paediatric gliomas, the identification of a subtype of ultra-mutated IDH-wt GBM may have implications for immunotherapy.
Identifiants
pubmed: 31480372
pii: cancers11091279
doi: 10.3390/cancers11091279
pmc: PMC6770353
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 12182
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Fam Cancer. 2019 Apr;18(2):173-178
pubmed: 30368636
Cancer Cell. 2019 Apr 15;35(4):692-704.e12
pubmed: 30905762
BMC Bioinformatics. 2018 Jun 14;19(1):224
pubmed: 29898651
PLoS One. 2013 Jun 06;8(6):e62692
pubmed: 23762227
J Clin Oncol. 2016 Jul 1;34(19):2206-11
pubmed: 27001570
Acta Neuropathol. 2015 Jun;129(6):829-48
pubmed: 25943888
Nat Commun. 2018 May 1;9(1):1746
pubmed: 29717118
Acta Neuropathol. 2018 Nov;136(5):793-803
pubmed: 30187121
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Neurosurg. 2019 Apr 5;:1-12
pubmed: 30952131
Oncologist. 2017 Dec;22(12):1478-1490
pubmed: 28912153
Genes Chromosomes Cancer. 2014 Jul;53(7):589-605
pubmed: 24706357
Front Genet. 2012 Mar 15;3:35
pubmed: 22435069
Brain Pathol. 2016 Jul;26(4):517-22
pubmed: 26443480
PLoS One. 2013 Jun 28;8(6):e67421
pubmed: 23840696
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Neuro Oncol. 2015 Oct;17(10):1356-64
pubmed: 25740784
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Acta Neuropathol. 2010 Dec;120(6):707-18
pubmed: 21088844
Bioinformatics. 2010 Aug 15;26(16):2069-70
pubmed: 20562413
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Discov Med. 2017 Feb;23(125):113-120
pubmed: 28371614
Brain Pathol. 2019 Nov;29(6):782-792
pubmed: 30861589
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Neuro Oncol. 2017 Aug 1;19(8):1047-1057
pubmed: 28371827
Brain Pathol. 2016 Sep;26(5):569-80
pubmed: 26517431
Ann Oncol. 2019 May 06;:null
pubmed: 31056702
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Bioinformatics. 2014 Dec 15;30(24):3443-50
pubmed: 25016581
Hum Pathol. 2019 Apr;86:170-181
pubmed: 30594748
Acta Neuropathol. 2015 Jan;129(1):133-46
pubmed: 25427834
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009